Treatment with the proteasome inhibitor bortezomib (PS-441, Velcade) results in Noxa mRNA and protein induction in both p53 wild-type and p53-null melanoma cells, but not in normal melanocytes [115]. Here, PMAIP1 is linked to melanoma.